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Background: High interdialytic weight gain (IDWG) is associated with adverse outcomes in hemodialysis
(HD) patients. We identified temporal and regional trends in IDWG, predictors of IDWG, and associations of
IDWG with clinical outcomes.
Study Design: Analysis 1: sequential cross-sections to identify facility- and patient-level predictors of IDWG
and their temporal trends. Analysis 2: prospective cohort study to assess associations between IDWG and
mortality and hospitalization risk.
Setting & Participants: 21,919 participants on HD therapy for 1 year or longer in the Dialysis Outcomes
and Practice Patterns Study (DOPPS) phases 2 to 5 (2002-2014).
Predictors: Analysis 1: study phase, patient demographics and comorbid conditions, HD facility practices.
Analysis 2: relative IDWG, expressed as percentage of post-HD weight (,0%, 0%-0.99%, 1%-2.49%, 2.5%-
3.99% [reference], 4%-5.69%, and $5.7%).
Outcomes: Analysis 1: relative IDWG as a continuous variable using linear mixed models; analysis
2: mortality; all-cause and cause-specific hospitalization using Cox regression, adjusting for potential
confounders.
Results: From phase 2 to 5, IDWG declined in the United States (20.29 kg; 20.5% of post-HD weight),
Canada (20.25 kg; 20.8%), and Europe (20.22 kg; 20.5%), with more modest declines in Japan and
Australia/New Zealand. Among modifiable factors associated with IDWG, the most notable was facility
mean dialysate sodium concentration: every 1-mEq/L greater dialysate sodium concentration was
associated with 0.13 (95% CI, 0.11-0.16) greater relative IDWG. Compared to relative IDWG of 2.5% to
3.99%, there was elevated risk for mortality with relative IDWG $ 5.7% (adjusted HR, 1.23; 95% CI,
1.08-1.40) and elevated risk for fluid-overload hospitalization with relative IDWG $ 4% (HRs of 1.28
[95% CI, 1.09-1.49] and 1.64 [95% CI, 1.27-2.13] for relative IDWGs of 4%-5.69% and $5.7%,
respectively).
Limitations: Possible residual confounding. No dietary salt intake data.
Conclusions: Reductions in IDWG during the past decade were partially explained by reductions in dial-
ysate sodium concentration. Focusing quality improvement strategies on reducing occurrences of high IDWG
may improve outcomes in HD patients.
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Wong et alIn hemodialysis (HD) patients, high interdialyticweight gain (IDWG), high ultraﬁltration rate, and
short session duration have been associated with poor
outcomes.1-11 Speciﬁcally, high IDWG, as deﬁned by
various cutoffs, has been associated with increased
risks for left ventricular hypertrophy, intradialytic
hypotension, and all-cause and cardiovascular mor-
tality.3-5,7,12-14 In the United States, HD patients have
high rates of hospitalizations due to ﬂuid overload
(13.7/100 patient-years), which entail signiﬁcant
health care costs.15
Recently, large dialysis organizations in the United
States have proposed a “Volume First” quality
improvement initiative, highlighting volume control as a
primary goal of dialysis care.16 Their recommendations
to achieve better control of IDWG include a “4-hour
ﬁrst” policy for HD session duration, dietary sodium
restriction, and dialysate sodium concentration of 134 to
138mEq/L. In 2013, a Technical Expert Panel convened
by the Centers for Medicare & Medicaid Services pro-
posed a maximum ultraﬁltration rate of 13 mL/kg/h for
HD patients. Potential measures related to session
duration, IDWG, and rate of hospitalization due to ﬂuid
overload were discussed, but not proposed.17
In view of these clinical associations and new ini-
tiatives in the dialysis community, we investigated
international trends in IDWG using data from the
Dialysis Outcomes and Practice Patterns Study
(DOPPS) from 2002 to 2014. We hypothesized that
any observed decline in IDWG would likely be due to
HD facility practices intended to limit IDWG or avoid
high IDWG and would be associated with a favorable
effect on outcomes. Therefore, the aims of our study
were to examine: (1) temporal trends in IDWG, session
duration, and ultraﬁltration rate in different regions; (2)
associations of patient characteristics and HD facility
practices with IDWG; and (3) associations of IDWG
with mortality and hospitalizations.
METHODS
Patient Characteristics and Study Design
DOPPS is a prospective cohort study of adults (aged $18 years)
receiving in-center HD. Study methods have been published.18,19
DOPPS received institutional review board approval from Ethical
and Independent Review Services (study number: 98004-19), and
patient consent was obtained as required by local medical research
ethics committees. All analyses used data from DOPPS phases 2
(2002-2004), 3 (2005-2008), 4 (2009-2011), and 5 (2012-2014).
Patients from prevalent cross-sections within each phase, from 486
HD facilities in 12 countries, were included. Due to the relative
instability of residual kidney function and IDWG during the ﬁrst
year after HD therapy initiation,20 patients enrolled during their ﬁrst
year of dialysis therapy were excluded. Patients on an HD schedule
other than thrice weekly and those with dialysate sodium concen-
tration proﬁling or missing IDWG data were excluded.
The study sample ﬂow chart is shown in Fig S1 (provided as
online supplementary material). Baseline characteristics, comorbid
data, and laboratory measurements were obtained at study entry.368To estimate baseline IDWG, we used mean pre- and post-HD
weight data from 3 consecutive HD sessions collected at enroll-
ment (for all phases except phase 3) or at 4 months after enroll-
ment (for phase 3). Pre- and post-HD blood pressure (BP) data
were similarly collected. Patients were weighted based on the in-
verse of the sampling proportion within each facility. Data
regarding the use of dry weight assessment techniques (relative
plasma volume monitoring, bioimpedance, and orthostatic BP
measurements) were extracted from medical director surveys in
phases 4 and 5.
Statistical Analyses
Descriptive statistics were used to examine cross-sections of
patients from DOPPS phases 2 to 5 at baseline. Trends in baseline
IDWG (expressed as absolute weight and as percentage of post-
dialysis weight [relative IDWG]), session duration, ultraﬁltration
rate, pre- and post-HD systolic BP (SBP), DSBP (calculated as
pre-HD SBP minus post-HD SBP), normalized protein catabolic
rate (nPCR), and serum albumin level in the United States, Can-
ada, Europe (including Belgium, France, Germany, Italy, Spain,
Sweden, and the United Kingdom), Japan, and Australia/New
Zealand across study phases were graphed and the existence of a
trend was tested using linear regression, at both the patient- and
facility-level (eg, facility mean). Distributions of patients by
relative IDWG categories (,0%, 0%-0.99%, 1%-2.49%, 2.5%-
3.99%, 4%-5.69%, and $5.7%) were also calculated. The 5.7%
cutoff has been used in previous studies and represents a 4-kg
IDWG in a patient with a post-HD weight of 70 kg.7
Multivariable linear mixed-model regression was used to assess
the association between baseline relative IDWG as a continuous
variable and patient- and facility-level covariates. Patient-level
covariates included age, sex, race, dialysis vintage, post-HD
weight, diabetes mellitus, congestive heart failure (CHF), resid-
ual kidney function (deﬁned as urine output . 200 mL/d) at
enrollment, serum albumin level, serum creatinine level, nPCR,
pre-HD SBP, and pre-HD serum sodium concentration, whereas
facility-level characteristics included mean dialysate sodium con-
centration, mean session duration, proportion of patients pre-
scribed loop diuretics, dietitian at HD facility, and frequency of
dietitian counseling for patients with high IDWG. Models were
adjusted for DOPPS study phase, region, and 12 other comorbid
conditions (listed in Tables 1 and 2). Models accounted for facility
clustering effects using a mixed-model approach. Patients
belonging to facilities that reported any of the facility-level
covariates for fewer than 10 of their patients were excluded
when calculating facility-level covariates. Mean facility pre-HD
BP targets were missing for w45% of patients; therefore, this
variable was not included in analyses. The following sensitivity
analyses were performed: (1) inclusion of sodium gradient (equal
to dialysate sodium concentration minus serum sodium concen-
tration) as a model covariate, instead of dialysate sodium con-
centration and serum sodium concentration as separate covariates;
(2) inclusion of creatinine index21 as a covariate in lieu of serum
creatinine level, and (3) addition of catheter use as a covariate.
Cox models were used to evaluate the association of the
mentioned relative IDWG categories with all-cause mortality.
Time at risk started at baseline IDWG data collection and
continued until the earliest of death or up to 7 days after departure
from the facility for kidney transplantation, change of treatment
modality, withdrawal from dialysis therapy, return of kidney
function, or transfer to another facility. Follow-up time was
censored at the end of each study phase for those who did not
depart from the facility. Cox models were also used to analyze the
associations of relative IDWG with time to ﬁrst hospitalization or
death. All-cause hospitalization, as well as hospitalizations due to:
(1) ﬂuid overload (diagnoses classiﬁed as ﬂuid overload, CHF, orAm J Kidney Dis. 2017;69(3):367-379
Table 1. Patient Characteristics by Relative IDWG Category at Baseline
Characteristic
All Patients
(N 5 21,919)
Relative IDWG (Percentage of Post-HD Weight)
,0%
(n 5 179)
0%-0.99%
(n 5 887)
1%-2.49%
(n 5 4,876)
2.5%-3.99%
(n 5 8,677)
4%-5.69%
(n 5 5,624)
$5.7%
(n 5 1,676)
Age, y 63.2 6 14.3 63.2 6 15.2 65.9 6 14.7 66.3 6 13.7 63.96 13.9 60.5 6 14.4 57.7 6 14.7
Male sex 58% 48% 57% 56% 60% 60% 54%
Race
Black 10% 6% 8% 11% 11% 9% 7%
White 59% 80% 80% 72% 61% 47% 38%
Asian 26% 8% 10% 11% 23% 40% 50%
Other or missing 5% 7% 2% 5% 5% 4% 5%
Presence of RKF 26% 68% 57% 35% 24% 17% 14%
IDWG, % of post-HD
weight
3.4%6 1.6% 20.6% 6 0.6% 0.6% 6 0.3% 1.9%6 0.4% 3.3%6 0.4% 4.7% 6 0.5% 6.7% 6 1.1%
Session duration, min 240 [214-241] 230 [195-240] 240 [210-240] 240 [210-242] 240 [212-241] 240 [227-240] 240 [238-247]
Coronary artery disease 40% 46% 41% 42% 41% 39% 37%
Cerebrovascular disease 16% 19% 17% 18% 16% 15% 12%
Congestive heart failure 28% 23% 23% 28% 28% 28% 31%
HTN 82% 81% 81% 81% 83% 81% 80%
Peripheral vascular
disease
25% 30% 24% 27% 27% 23% 20%
Other cardiovascular
diseasea
33% 28% 31% 33% 33% 32% 31%
Cancer (nonskin) 12% 16% 16% 15% 12% 10% 9%
Diabetes mellitus 38% 26% 30% 39% 39% 37% 36%
Gastrointestinal bleed 5% 6% 5% 5% 5% 5% 5%
HIV/AIDS 1% 0% 1% 1% 1% 2% 2%
Lung disease 11% 9% 10% 12% 11% 10% 9%
Neurologic disease 11% 15% 11% 11% 10% 10% 12%
Psychiatric disorder 14% 18% 14% 15% 15% 14% 13%
Recurrent cellulitis/
gangrene
8% 7% 8% 9% 9% 8% 7%
Dialysis vintage, y 4.2 [2.3-7.9] 2.9 [1.6-6.1] 3.1 [1.7-5.3] 3.5 [2.0-6.3] 4.2 [2.3-7.6] 5.2 [2.7-9.9] 5.9 [3.0-10.5]
Catheter for
vascular access
15% 11% 15% 15% 13% 14% 11%
Postdialysis weight, kg 69 6 19 66 6 17 72 6 18 75 6 21 71 6 19 63 6 17 57 6 15
Predialysis SBP, mm Hg 144 6 22 137 6 22 1416 21 142 6 22 1446 22 1466 23 149 6 24
Postdialysis SBP, mm Hg 134 6 22 135 6 22 1386 22 134 6 22 1336 22 1336 22 134 6 23
Serum albumin, g/dL 3.86 0.5 3.86 0.7 3.8 6 0.5 3.86 0.5 3.86 0.5 3.8 6 0.4 3.8 6 0.5
nPCR, g/kg/d 1.01 6 0.24 0.87 6 0.25 0.87 6 0.22 0.95 6 0.23 1.026 0.24 1.06 6 0.23 1.10 6 0.23
Pre-HD serum
sodium, mEq/L
1386 3 1386 4 1396 3 1396 3 138 6 3 1386 3 1376 4
Sodium gradient, mEq/Lb 1.26 3.9 0.56 4.1 20.16 3.8 0.26 3.7 1.16 3.7 2.0 6 3.8 2.7 6 4.2
Loop diuretic use 20% 37% 33% 24% 20% 16% 13%
No. of anti-HTN
medications per pt
1.86 1.5 1.86 1.6 1.8 6 1.5 1.76 1.5 1.76 1.5 1.8 6 1.6 2.0 6 1.6
Serum creatinine, mg/dL 9.36 2.9 7.36 3.2 7.6 6 2.6 8.56 2.7 9.36 2.8 10.06 3.0 10.0 6 2.9
Creatinine index, mg/kg/d 20 6 3 19 6 3 196 3 20 6 3 20 6 3 21 6 3 21 6 3
Note: Values for categorical variables are given as percentages; values for continuous variables, as mean 6 standard deviation or
for skewed distributions, as median [interquartile range]. Conversion factor for serum creatinine in mg/dL to mmol/L, 388.4.
Abbreviations: HD, hemodialysis; HIV, human immunodeficiency virus; HTN, hypertension; IDWG, interdialytic weight gain; nPCR,
normalized protein catabolic rate; pt, patient; RKF, residual kidney function; SBP, systolic blood pressure.
aIncludes cardiac arrest, atrial fibrillation, other arrhythmia, permanent pacemaker, automatic implanted cardiac defibrillator, peri-
carditis, valvular heart disease, and prosthetic heart valve (valve replacement).
bDialysate sodium to pre-HD serum sodium gradient 5 dialysate sodium concentration 2 serum sodium concentration.
International Trends in Interdialytic Weight Gainpulmonary edema), (2) cardiovascular causes other than those
listed in (1), and (3) all other causes were evaluated. Models were
adjusted for all mentioned covariates, except for use of loop di-
uretics and dietitian-related variables. Cox models accounted for
facility clustering effects with a robust sandwich estimator for the
covariance matrix.Am J Kidney Dis. 2017;69(3):367-379To examine the robustness of results for the mortality and
hospitalization analyses, the following sensitivity analyses were
performed: (1) excluding those with relative IDWG # 1%, in or-
der to exclude patients with high urine output and those with acute
illness or other causes of low oral intake; (2) for the ﬂuid-overload
hospitalization analysis, removing adjustment for CHF because369
Table 2. Baseline Patient Characteristics and Facility Practices by DOPPS Phase
Phase 2
(2002-2004)
Phase 3
(2005-2008)
Phase 4
(2009-2011)
Phase 5
(2012-2014)
P for
Trend
No. of patients 4,646 5,257 6,599 5,417
Patient characteristics
Age, y 61.7 6 14.4 63.4 6 14.1 64.1 6 14.4 63.16 14.2 ,0.001
Male sex 58% 58% 58% 60% 0.009
Race
Black 7% 7% 14% 11% ,0.001
White 61% 60% 58% 57% 0.06
Asian 28% 28% 23% 26% 0.7
Other or missing 4% 5% 5% 6% ,0.001
Presence of RKF 23% 31% 24% 25% 0.4
Relative IDWG, % of post-HD weight 3.7% 6 1.7% 3.5% 6 1.6% 3.4% 6 1.5% 3.3% 6 1.5% ,0.001
Session duration, min 240 [225-240] 240 [225-242] 240 [210-244] 240 [217-241] 0.007
Coronary artery disease 42% 52% 38% 31% ,0.001
Cerebrovascular disease 16% 18% 16% 13% ,0.001
Congestive heart failure 25% 38% 28% 20% ,0.001
HTN 76% 81% 84% 84% ,0.001
Peripheral vascular disease 24% 28% 28% 22% 0.6
Other cardiovascular diseasea 38% 39% 31% 24% ,0.001
Cancer (nonskin) 10% 12% 13% 13% ,0.001
Diabetes mellitus 28% 35% 44% 42% ,0.001
Gastrointestinal bleed 5% 5% 5% 4% 0.004
HIV/AIDS 1% 1% 1% 1% 0.5
Lung disease 9% 11% 12% 10% 0.2
Neurologic disease 11% 12% 11% 9% ,0.001
Psychiatric disorder 16% 11% 16% 14% 0.9
Recurrent cellulitis/gangrene 7% 8% 10% 7% 0.5
Dialysis vintage, y 4.1 [2.2-8.0] 4.1 [2.1-7.9] 4.3 [2.4-8.1] 4.4 [2.4-7.9] ,0.001
Catheter for vascular access 11% 15% 15% 13% 0.2
Postdialysis weight, kg 65 6 17 67 6 18 72 6 21 716 20 ,0.001
Predialysis SBP, mm Hg 145 6 22 1446 22 144 6 23 1436 23 ,0.001
Postdialysis SBP, mm Hg 134 6 22 1346 22 133 6 22 1346 22 0.006
Serum albumin, g/dL 3.86 0.4 3.8 6 0.5 3.86 0.5 3.86 0.4 0.9
nPCR, g/kg/d 1.05 6 0.25 1.01 6 0.23 1.01 6 0.24 0.996 0.24 ,0.001
Pre-HD serum sodium, mEq/L 1386 3 1386 3 1396 3 1386 3 0.002
Sodium gradient, mEq/Lb 1.76 3.9 1.6 6 3.9 0.86 3.9 0.96 3.7 ,0.001
Loop diuretic use 17% 22% 19% 22% ,0.001
No. of anti-HTN medications per pt 1.56 1.4 1.8 6 1.5 1.96 1.6 1.86 1.6 ,0.001
Serum creatinine, mg/dL 9.86 2.9 9.3 6 2.9 9.16 3.0 9.06 2.8 ,0.001
Creatinine index, mg/kg/d 21 6 3 20 6 3 20 6 3 20 6 3 ,0.001
Facility practices
Facility mean spKt/Vc 1.45 6 0.15 1.48 6 0.16 1.55 6 0.14 1.576 0.15 ,0.001
Facility dialysate sodium, mEq/Lc 1406 2 1406 2 1396 2 1396 2 ,0.001
Facility session duration, minc 240 6 24 2416 23 235 6 24 2396 23 ,0.001
Predialysis SBP target, mm Hgc 143 6 10 1456 12 148 6 15 1496 13 ,0.001
Predialysis DBP target, mm Hgc 87 6 6 87 6 7 91 6 7 89 6 6 ,0.001
Dietitian assessment for high IDWGd,e 3.66 1.4 3.6 6 1.4 3.96 1.1 3.96 1.2 ,0.001
Has dietitiand 57% 42% 58% 67% ,0.001
Note: Values for categorical variables are given as percentages; values for continuous variables, as mean 6 standard deviation or
for substantially skewed distributions, as median [interquartile range]. Values are unadjusted, except for P values for the linear trend,
which are adjusted for region. Conversion factor for serum creatinine in mg/dL to mmol/L, 388.4.
Abbreviations: DBP, diastolic blood pressure; DOPPS, Dialysis Outcomes and Practice Patterns Study; HD, hemodialysis; HIV,
human immunodeficiency virus; HTN, hypertension; IDWG, interdialytic weight gain; nPCR, normalized protein catabolic rate; pt,
patient; RKF, residual kidney function; SBP, systolic blood pressure; spKt/V, single-pool Kt/V.
aIncludes cardiac arrest, atrial fibrillation, other arrhythmia, permanent pacemaker, automatic implanted cardiac defibrillator, peri-
carditis, valvular heart disease, and prosthetic heart valve (valve replacement).
bDialysate sodium to pre-HD serum sodium gradient 5 dialysate sodium concentration 2 serum sodium concentration.
cBasedonpatient-leveldata.Facilitymeandataareweightedby thenumberofpatientswithineach facilitywithineachstudyphaseandoverall.
dBased on unit practices surveys from each facility.
eSurvey question was, “How often does the dietitian (or other provider responsible for nutritional management in your unit) conduct a
special dietary assessment and counseling for patients large interdialytic weight gain without symptoms of fluid overload?” Responses
in ordinal scale were converted to numeric scale from 1 to 5: 1: never, 2: seldom, 3: about half the time, 4: usually, 5: always.
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(3) accounting for patient clustering (because 15%-39% of patients
in each country were included in both phases 4 and 5). Subgroup
analyses by residual kidney function (presence vs absence) at
enrollment among patients with HD vintage of 1 year or longer, as
well as among patients with HD vintage less than 1 year (a group
excluded from primary analyses) were also performed.
We used the sequential regression multiple imputation method
implemented by IVEware (version 0.2; Institute for Social
Research, University of Michigan) to impute missing data for
linear mixed models and Cox models.22 All missing variables
except for IDWG were imputed. Imputation used 10 iterations and
assumed that missing data were missing at random, where every
variable was used to impute missing values. As sensitivity anal-
ysis, we also used missingness indicator methods. All statistical
analyses were carried out using SAS, version 9.3 (SAS
Institute Inc).
RESULTS
Patient Characteristics
Among 21,919 DOPPS participants included in the
analysis from phases 2 to 5, median follow-up was
2.0 (interquartile range, 1.0-2.6) years. Baseline pa-
tient characteristics are listed by relative IDWG
category in Table 1. Patient and facility characteristics
by DOPPS study phase are shown in Table 2. Mean
age was 63.26 14.3 years, 58% were men, and 38%
had diabetes. Patients with relative IDWG $ 5.7% of
post-HD weight were more likely to be of youngerFigure 1. Trends in interdialytic weight gain (IDWG) by region a
phases among 21,919 patients (phase 2: 2002-2004, phase 3: 2005
IDWG, as percent of posthemodialysis (post-HD) weight; 95% confi
dence intervals are shown. (C) Proportion of patients by relative
facility-level relative IDWG (percent age of post-HD weight). The bo
to 95th percentile. *P for trend , 0.05. **P for trend , 0.001. Abbre
Am J Kidney Dis. 2017;69(3):367-379age and Asian race and have longer dialysis vintage,
lower post-HD weight, higher nPCR, higher pre-HD
SBP, and larger dialysate-to-serum sodium gradient
and were less likely to be on loop diuretics and be
dialyzed with a catheter.Trends in IDWG, Session Duration, Ultraﬁltration
Rate, BP, and Nutritional Parameters
During the 10-year period, both absolute and relative
IDWGdeclined in the United States (20.29 kg;20.5%
of post-HD weight; P for trend , 0.001), Canada
(20.25 kg; 20.8% of post-HD weight; P for trend ,
0.001), and Europe (20.22 kg; 20.5% of post-HD
weight; P for trend , 0.001; Fig 1A and B).
Although absolute IDWG did not clearly decrease in
Australia/NewZealand or Japan, both regions exhibited
declines in relative IDWG (Australia/New
Zealand: 20.3% of post-HD weight [P for trend 5
0.03]; Japan:2 0.2% of post-HD weight [P for trend5
0.02]). Among all regions, relative IDWG was highest
in Japan throughout all study phases. The proportion of
patients in the highest relative IDWG category
($5.7%) declined across all regions over the same
period (Fig 1C). Facility-level relative IDWG and
between-facility variability in relative IDWG tended tocross Dialysis Outcomes and Practice Patterns Study (DOPPS)
-2008, phase 4: 2009-2011, phase 5: 2012-2014). (A) Relative
dence intervals are shown. (B) Absolute IDWG (kg); 95% confi-
IDWG (percent age of post-HD weight) category. (D) Mean
x shows the 25th to 75th percentile, and the whiskers, the 5th
viations: ANZ, Australia/New Zealand; US, United States.
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Wong et aldecrease over time (Fig 1D). Overall, patients without
residual kidney function at study entry had higher
relative IDWG compared with those with residual
kidney function, but both subgroups showed trends of
decreasing relative IDWG over the 10-year study
period in most countries, except for Japan and
Australia/New Zealand, in which relative IDWG did
not change signiﬁcantly among patients with residual
kidney function (P for trend . 0.4; ﬁgures a and b of
Item S1). Slight increases in baseline post-HD weight
were observed across regions (Fig S2).
From DOPPS phases 2 to 5, ultraﬁltration rate
declined in a similar pattern as shown for relative
IDWG (ﬁgure a of Item S2). The largest decline in
ultraﬁltration rate was observed in Canada, followed by
Europe, the United States, and Australia/New Zealand;
there was little change in Japan. Session duration
changed incrementally during the 10-year period, with
the largest increase observed in Australia/New Zealand
(by 12.9 minutes) and much smaller changes in other
regions (ﬁgure b of Item S2).
Reductions in pre-HD SBP from phase 2 to 5 were
observed in all regions, ranging from 22.2 mm Hg in
Japan to25.9 mm Hg in Canada (Fig 2A). Patterns in
post-HD SBP were variable, and there was no sus-
tained trend over time in any region except for the
United States, which showed a roughly linear decline
by 3.9 mm Hg from phase 2 to 5 (P for trend, 0.001;
Fig 2B). In all regions, there was a decline in DSBPFigure 2. Trends in systolic blood pressure (SBP) by region ac
phases (phase 2: 2002-2004, phase 3: 2005-2008, phase 4: 2009-201
intervals are shown. (A) Prehemodialysis (pre-HD) SBP. (B) Post-H
, 0.05. **P for trend , 0.001. Abbreviations: ANZ, Australia/New Z
372during the 10 years, ranging from 21.1 mm Hg in the
United States to 25.6 mm Hg in Australia/New
Zealand (Fig 2C). In the United States and Japan, the
mean number of antihypertensive medications per
patient increased over the 10-year period (from 1.5 to
1.8 in Japan and from 2.0 to 2.4 in the United States;
P for trend , 0.001; Fig S3).
nPCR decreased slightly in Japan and Europe
(20.08 g/kg/d over 10 years; P for trend , 0.001),
with even smaller changes in other regions (ﬁgure a
of Item S3). Changes in serum albumin levels were
unremarkable (by #0.11 g/dL over 10 years; ﬁgure b
of Item S3).
Use of dry weight assessment techniques among
facilities is shown in Table S1.
Associations of Patient and Facility Characteristics
With IDWG
Linear regression coefﬁcients of covariates associ-
ated with relative IDWG levels are shown in Table 3.
Based on ranking of F statistic values, covariates most
closely associated with higher relative IDWG were (in
descending order) higher nPCR, lower post-HD
weight, lower serum sodium concentration, younger
patient age, absence of residual kidney function,
higher pre-HD SBP, higher facility mean dialysate
sodium concentration, CHF, male sex, diabetes, re-
gion (Japan and United States), greater serum creati-
nine level, lung disease, lower serum albumin level,ross Dialysis Outcomes and Practice Patterns Study (DOPPS)
1, phase 5: 2012-2014) among 21,845 patients; 95% confidence
D SBP. (C) DSBP (pre-HD SBP – post-HD SBP). *P for trend
ealand; US, United States.
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Table 3. Adjusted Differences in Mean Relative IDWG by Patient Characteristics and Facility Practices, Based on Multivariable Linear
Regression Model
Predictor Variable Relative IDWG (95% CI) F Value
nPCR, per 0.1 g/kg/d greater 0.13 (0.12 to 0.14) 1,017.5
Mean postdialysis weight, per 10 kg greater 20.17 (20.18 to 20.16) 786.3
Serum sodium concentration, per 1 mEq/L greater 20.07 (20.08 to 20.07) 704.8
Age, per 10 y older 20.18 (20.19 to 20.16) 558.1
Residual kidney function, yes/no 20.45 (20.50 to 20.40) 388.1
Pre-HD SBP, per 10 mm Hg greater 0.05 (0.04 to 0.06) 137.2
Facility mean dialysate sodiuma per 1 mEq/L greaterb 0.13 (0.11 to 0.16) 120.2
Congestive heart failure 0.21 (0.17 to 0.26) 91.4
Male sex 0.16 (0.12 to 0.20) 66.4
Diabetes 0.17 (0.13 to 0.21) 64.3
Region
Australia/New Zealand 21.00 (21.18 to 20.82) 48.2 (for region)
Canada 20.57 (20.73 to 20.40) —
Europe 20.50 (20.61 to 20.39) —
Japan 0.09 (20.09 to 0.27) —
United States Reference group —
Serum creatinine, per 1 mg/dL greater 0.03 (0.02 to 0.04) 42.7
Lung disease 0.13 (0.07 to 0.19) 18.8
Serum albumin, per 1 g/dL greater 20.09 (20.13 to 20.04) 15.5
Cerebrovascular disease 20.09 (20.14 to 20.04) 13.3
Hypertension 0.09 (0.04 to 0.14) 12.5
Facility mean session duration, per 30-min longerb 0.09 (0.04 to 0.14) 12.2
Other cardiovascular disease 0.06 (0.02 to 0.10) 8.5
Cancer (nonskin) 20.07 (20.12 to 20.01) 6.4
Study phase 20.04 (20.07 to 20.01) 5.4
Note: N 5 29,919. Relative IDWG is percentage of post-HD weight. Results (b coefficients) are from a multivariable linear regression
including all covariates listed in the table, plus the following covariates with smaller F statistics than listed above: race, dialysis vintage,
coronary artery disease, peripheral vascular disease, HIV, neurologic disease, gastrointestinal bleed, psychiatric disorder, recurring
cellulitis/gangrene, use of loop diuretics, dietitian at HD unit, and dietitian assessment for high IDWG. Conversion factor for serum
creatinine in mg/dL to mmol/L, 388.4.
Abbreviations: CI, confidence interval; HD, hemodialysis; IDWG, interdialytic weight gain; nPCR, normalized protein catabolic rate;
SBP, systolic blood pressure.
aDialysate sodium to pre-HD serum sodium gradient 5 dialysate sodium 2 serum sodium concentration.
bModifiable facility factors.
International Trends in Interdialytic Weight Gainabsence of cerebrovascular disease, hypertension,
longer facility mean session duration, other cardio-
vascular disease, absence of cancer comorbid condi-
tions, and earlier study phase. On average, Australia/
New Zealand, Canada, and Europe had lower relative
IDWGs than the United States, whereas there was no
signiﬁcant difference between Japan and the United
States.
Dialysate sodium concentration was the most sig-
niﬁcant facility-level variable: every 1-mEq/L greater
dialysate sodium concentration was associated with
0.13 (95% conﬁdence interval [CI], 0.11-0.16) greater
relative IDWG. Temporal trends in dialysate sodium
concentration, serum sodium concentration, and so-
dium gradient are shown in Fig 3. From phase 2 to 5,
facility mean dialysate sodium concentration demon-
strated statistically signiﬁcant declines in all
regions, most notably in the United States (21.7
mEq/L) and Canada (21.1 mEq/L); declines were ,1
mEq/L in Australia/New Zealand, Europe, and Japan.Am J Kidney Dis. 2017;69(3):367-379Correspondingly, from phase 2 to 5, there were de-
clines in sodium gradient in the United States (21.1
mEq/L; P for trend, 0.001), Europe (21.0 mEq/L; P
for trend , 0.001), and Canada (21.0 mEq/L; P for
trend 5 0.05), but not in other regions. Sensitivity
analysis including sodium gradient in lieu of serum
sodium concentration and dialysate sodium concen-
tration in the regression model demonstrated that
every 1-mEq/L greater sodium gradient was associ-
ated with 0.07 (95% CI, 0.07-0.08) greater relative
IDWG. The positive association between facility-
level sodium gradient and relative IDWG is shown
in Fig S4.
Sensitivity analysis conducted using creatinine in-
dex showed an association of 0.04 (95% CI, 0.02-
0.05) greater relative IDWG per 1-mg/kg/d greater
creatinine index, compared to the 0.03 (95% CI, 0.02-
0.04) greater relative IDWG per 1-mg/dL greater
serum creatinine concentration that is shown
in Table 3. Sensitivity analysis including catheter373
Figure 3. Trends in (A) dialysate sodium (DNa) and (B) serum sodium (SNa) and (C) sodium gradient (GNa 5 DNa 2 SNa) values
by region across Dialysis Outcomes and Practice Patterns Study (DOPPS) phases (phase 2: 2002-2004, phase 3: 2005-2008, phase
4: 2009-2011, and phase 5: 2012-2014), among 19,192 patients; 95% confidence intervals are shown. *P for trend , 0.05. **P for
trend , 0.001. Abbreviations: ANZ, Australia/New Zealand; US, United States.
Wong et aluse in the model demonstrated that catheter use
was associated with lower relative IDWG (b
coefﬁcient, 20.18; 95% CI, 20.24 to 20.13), while
all other covariates were essentially unchanged.
Associations Between IDWG and Risks for Mortality
and Hospitalization
During phases 2 to 5, there were 5,082 (23%)
deaths and 14,366 (66%) patients were hospitalized at
least once during a study phase. The analysis of
cause-speciﬁc hospitalization risk included 19,000
patients. There were 1,127 hospitalizations due to
ﬂuid overload, 4,321 due to cardiovascular causes,
and 11,209 due to other causes. These were not
mutually exclusive; the same patient could have each
type of hospitalization, and some patients were not
hospitalized during follow-up.
All-cause mortality among all patients was higher
for relative IDWG $ 5.7% (fully adjusted hazard
ratio [HR], 1.23; 95% CI, 1.08-1.40) compared to
the reference category of relative IDWG 2.5% to
3.99%, but there was no meaningful difference in
mortality risk with other IDWG categories. As
shown in Fig 4, all-cause mortality risk was similar
among those with and without residual kidney
function in all relative IDWG categories except for
those with relative IDWG , 1% (comprising ,5%
of all patients), which demonstrated apparent374differences in the point estimates but with very wide
overlapping CIs (with residual kidney function: HRs
of 0.82 [95% CI, 0.49-1.37] for relative
IDWG , 0% and 1.22 [95% CI, 1.09-1.33] for
relative IDWG of 0%-0.99%; without residual kid-
ney function: HRs of 1.12 [95% CI, 0.66-1.90] and
1.01 [95% CI, 0.79-1.30], respectively).
All-cause hospitalization was higher in the relative
IDWG $ 5.7% (adjusted HR, 1.18; 95% CI, 1.10-
1.27) and the 1% to 2.49% (adjusted HR, 1.06; 95%
CI, 1.01-1.11) groups, whereas all other relative
IDWG categories were not signiﬁcantly different
from the reference category (Fig 5). Relative IDWG
was positively and monotonically associated with
ﬂuid overload hospitalization. Compared to relative
IDWG of 2.5% to 3.99%, relative IDWG $ 4% was
associated with higher risk for hospitalizations due to
ﬂuid overload (HRs of 1.28 [95% CI, 1.09-1.49] and
1.64 [95% CI, 1.27-2.13] for relative IDWGs of 4%-
5.69% and $5.7%, respectively), whereas there were
reduced risks in the relative IDWG , 0% and 0% to
0.99% groups (HRs of 0.43 [95% CI, 0.17-1.11] and
0.80 [95% CI, 0.56-1.15], respectively). Hospitaliza-
tions due to other cardiovascular causes were
increased in only the relative IDWG $ 5.7% group
(HR, 1.21; 95% CI, 1.05-1.40). Results for hospital-
ization analyses were similar for patients with and
without residual kidney function (Item S4).Am J Kidney Dis. 2017;69(3):367-379
Figure 4. Associations between relative interdialytic weight gain (IDWG) and risk for all-cause mortality in patients with and without
residual kidney function (RKF) among 17,864 patients (4,593 with RKF and 13,271 without RKF). Fully adjusted hazard ratios with 95%
confidence intervals (CIs) are shown. Abbreviation: HD, hemodialysis.
International Trends in Interdialytic Weight GainAll sensitivity analyses yielded materially
similar results to the primary analysis. Sensitivity
analysis accounting for patient clustering resulted
in HRs within 10% of those using models ac-
counting for facility clustering. A separate analysis
of patients with HD vintage less than 1 year did
not demonstrate clear associations between rela-
tive IDWG and mortality and hospitalization risk
(Item S5).Figure 5. Associations between relative interdialytic weight gain
(among 21,919 patients in all-cause hospitalization analysis and am
Fully adjusted hazard ratios with 95% confidence intervals (CIs) are
Am J Kidney Dis. 2017;69(3):367-379DISCUSSION
Our main ﬁndings in this large international cohort
study were: (1) relative IDWG and pre-HD SBP
showed variation between regions but consistently
declined over time in all regions; (2) as a corollary,
the proportion of patients with relative
IDWG $ 5.7% declined; (3) relative IDWG was
positively associated with facility mean dialysate(IDWG) and risk for all-cause and cause-specific hospitalizations
ong 19,000 patients in cause-specific hospitalization analysis).
shown. Abbreviation: HD, hemodialysis.
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Wong et alsodium concentration; (4) risk for mortality was
elevated at relative IDWG $ 5.7%; and (5) risk for
ﬂuid overload hospitalizations was elevated at relative
IDWG $ 4%.
Although previous studies have assessed the asso-
ciation of patient-level variables with IDWG,4,7,23 we
also considered facility practices. Of the facility fac-
tors analyzed, dialysate sodium concentration had the
strongest association with IDWG. Our analysis
showed a trend of declining dialysate sodium con-
centration across regions, with the greatest reductions
in both relative IDWG and dialysate sodium con-
centration in North America and the smallest re-
ductions in Japan. However, dialysate sodium
concentration accounted for only 0.13 greater relative
IDWG per 1-mEq/L greater dialysate sodium con-
centration, which suggests it played only a partial role
in explaining the decline in IDWG. Other factors that
may have contributed to regional differences in
IDWG trends include variations in dietary salt intake
and local HD guideline recommendations. Current
dialysis guidelines in Japan recommend that relative
IDWG over a 2-day period be within 6%,24 whereas
the European Best Practice Guidelines recommend
that relative IDWG not exceed 4% to 4.5% of dry
body weight.25 Overall, dialysate sodium concentra-
tion accounted for w29% of the decline in IDWG.
This translates to a reduction in IDWG by 0.1 kg for a
70-kg patient or w50 mL less ﬂuid intake per day.
Previous studies have also found a positive associa-
tion between dialysate sodium concentration and
IDWG.26,27 Although lower dialysate sodium con-
centration avoids intradialytic sodium loading, it has
been associated with longer recovery time, suggesting
that recovery symptoms may be due in part to
disequilibrium.28 The prognostic signiﬁcance of
dialysate sodium concentration remains controversial,
and confounding by indication for dialysate sodium
concentration prescription may account for some of
the variation in ﬁndings.29-32 Reduction of sodium
gradient as a means of reducing net sodium loading
and subsequent ﬂuid intake has been associated with
decreased IDWG.33,34 We demonstrated a positive
association between sodium gradient and IDWG, but
sodium gradient was not as strong a predictor of
IDWG as dialysate sodium concentration and serum
sodium concentration separately. A previous DOPPS
paper demonstrated that higher sodium gradient is
associated with elevated mortality, although the
serum sodium concentration component of the
gradient appears to be the main contributor rather than
dialysate sodium concentration.26
Another facility-level variable, facility mean ses-
sion duration, was positively associated with IDWG.
This demonstrates that there was likely some residual
confounding because those with high IDWG are more376likely to be prescribed longer session lengths. In a
previous DOPPS paper, a similar relationship be-
tween session duration and IDWG was found in the
patient-level analysis, but was not present in the
instrumental variable analysis, which was applied to
address treatment by indication bias.9
Often IDWG is used as a marker of adherence to
dietary restriction of salt and ﬂuid intake.7,10 How-
ever, IDWG is also an index of nutritional intake. We
found a positive association between IDWG and
nPCR, corroborating previous ﬁndings.35,36 Because
nPCR had minimal changes over time in all regions,
the decline in IDWG is not likely attributable to a
decline in protein intake. The serum albumin trend
was small and more variable between regions,
although serum albumin level is a suboptimal nutri-
tional indicator because it is also affected by
inﬂammation, acidosis, and ﬂuid status.37 It is likely
that the small group of patients with relative
IDWG , 0%, especially those with no residual
kidney function, had protein-energy wasting,
malnutrition, or intercurrent illness, as also sug-
gested by a signiﬁcantly lower mean nPCR in this
group. Catheter-related inﬂammation and associated
protein-energy wasting38-40 may be a possible
mechanism underlying the negative association be-
tween catheter use and IDWG.
We found a positive association between pre-HD
SBP and IDWG, and both parameters concurrently
declined across study phases. The link between
extracellular volume and BP in HD patients has
been demonstrated by earlier studies that found
volume control strategies such as “dry-weight
probing” were associated with decreased antihy-
pertensive medication use, lower left ventricular
mass, and lower IDWG.41-44 Because we observed
a consistent decline in pre-HD but not post-HD BP,
the pre-HD BP trend may be attributed to the
decline in IDWG. More intensive antihypertensive
drug use in Japan and the United States could also
have contributed to the decrease in BP. In
addition, BP is inﬂuenced by other factors
such as neurohormonal activation, dialysate
sodium concentration, and use of erythropoiesis-
stimulating agents.45
In our study, only the highest relative IDWG
category ($5.7%) demonstrated signiﬁcantly higher
mortality risk in the fully adjusted model. This ﬁnding
corroborates previous published reports demon-
strating an association between high IDWG and
mortality.1,3-5,7,10 In one of these previous studies,
higher IDWG was associated with better survival in
the unadjusted analyses, but only after adjustment for
case-mix and nutritional factors was higher IDWG
associated with greater mortality risk.4 In our study,
the relative IDWG $ 5.7% group showed decreasedAm J Kidney Dis. 2017;69(3):367-379
International Trends in Interdialytic Weight Gainmortality risk in the completely unadjusted analysis,
which was primarily driven by region, especially
Japan, where IDWG is relatively high and mortality is
relatively low. In the fully adjusted model, the asso-
ciation between relative IDWG $ 5.7% and greater
mortality risk was revealed.
Although IDWG represents salt and water intake
between sessions, it does not directly reﬂect under-
lying volume status. Patients with post-HD hypo-
volemia can have high IDWG.46 Coincident with the
trend of IDWG decline, mean post-HD weight actu-
ally increased slightly over the same period; however,
we cannot infer extracellular ﬂuid volume from this
measure. Furthermore, there is no current gold-
standard method to measure dry weight, although
previous studies using bioimpedance and relative
plasma volume have demonstrated associations be-
tween hypervolemia and mortality of greater magni-
tude (HR, 1.7-3.4) than the reported risk associated
with IDWG.47-49 Despite the shortcomings of IDWG
as a volume metric, we found a strong positive as-
sociation between high IDWG and risk for ﬂuid
overload hospitalization.
One of the strengths of this study is its large
multinational sample, allowing us to examine
changes in practice over time and across regions. In
terms of limitations, this study was observational and
therefore only associations can be identiﬁed, rather
than causal relationships. Residual confounding by
unmeasured covariates is also possible. Because
detailed dietary records were not collected, we could
not assess dietary salt intake, a pivotal determinant
of IDWG. We also could not account for intra-
dialytic oral intake or use of intravenous saline so-
lution for managing intradialytic hypotension.
Variations in the quality of the dietitian-patient in-
teractions and the effectiveness of dietitian strategies
to improve adherence to salt intake were not
captured by our data. Another limitation is that ﬂuid
overload hospitalizations may be misclassiﬁed as
heart failure or pulmonary edema. Therefore, all 3 of
these diagnoses were included in our deﬁnition of
ﬂuid overload hospitalization, an approach consis-
tent with other publications.15
In conclusion, our study illustrated overall re-
ductions in IDWG and a decline in the proportion of
patients with high IDWG across DOPPS regions over
a decade. Our ﬁndings of elevated risk for mortality at
relative IDWG $ 5.7% and elevated risk for ﬂuid
overload hospitalization at relative IDWG $ 4%
suggest that focusing quality improvement strategies
toward reducing high IDWG may improve patient
outcomes. Further studies are needed to examine the
impact of target weight assessment techniques and
patient-centered interventions to limit dietary sodium
intake on achievement of target weight and normalAm J Kidney Dis. 2017;69(3):367-379extracellular volume and on clinical outcomes such as
mortality, ﬂuid overload hospitalizations, and quality
of life.
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